FMA
SRPT icon

FNY Managed Accounts’s Sarepta Therapeutics SRPT Stock Holding History

FNY Managed Accounts’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-120
Closed -$3K – 805
2017
Q3 		$3K Buy
+120
New +$4.8K ﹤0.01% 562
2016
Q4 		– Sell
-10
Closed -$11.6K – 245
2016
Q3 		$11.6K Sell
10
-120
-92% -$3.63K 0.01% 311
2016
Q2 		$20.7K Buy
130
+114
+713% +$2.11K 0.02% 169
2016
Q1 		$40 Buy
+16
New +$280 ﹤0.01% 324

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FNY Managed Accounts's SRPT Position: Q2 2017 in Review

FNY Managed Accounts sold out of Sarepta Therapeutics (SRPT) in Q2 2017, closing a stake of 300 shares — an estimated $8K sold.

FNY Managed Accounts first reported a position in SRPT in Q4 2015 and held it in 3 quarters. The position peaked at $49.1K in Q3 2016. 190 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

  • FNY Managed Accounts reported no remaining Sarepta Therapeutics position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 300 Sarepta Therapeutics shares in Q2 2017, an estimated $8K.
  • FNY Managed Accounts first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 3 quarters.
  • FNY Managed Accounts's Sarepta Therapeutics position peaked at $49.1K in Q3 2016.
  • 190 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.